The PCS5 trial is a Canadian multicenter, open-label, phase III randomized trial that included men with histologically proven, clinically localized prostate cancer with ≥1 high-risk feature (s) ...
This was a single-center, retrospective analysis of 42 patients with MIBC who underwent TMT at the Moffitt Cancer Center between October 2019 and April 2024 and had ≥1 post-TMT ctDNA (Signatera TM) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback